Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2023 Earnings Call Transcript February 22, 2024 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.44. KYMR isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome to the […]
Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) traded down 1.9% during trading on Monday following insider selling activity. The stock traded as low as $36.22 and last traded at $36.49. 178,419 shares changed hands during trading, a decline of 80% from the average session volume of 883,645 shares. The stock had previously closed at […]
Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month […]
Jared Gollob, Chief Medical Officer of Kymera Therapeutics Inc (NASDAQ:KYMR), sold 46,137 shares of the company on February 9, 2024, according to a recent SEC Filing.